Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

About this update from Abbott Laboratories

[{"type":"list","items":[{"val":[{"type":"text","content":"Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percent","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint","length":119,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":407,"olType":false},{"type":"text","content":"ABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025.","length":150,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales1.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50, which excludes specified items and reflects growth of 12 percent.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year 2025 sales of $44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales2.","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year 2025 GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, which excludes specified items and reflects growth of 10 percent.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cance...

More updates from Abbott Laboratories